NCT02236052View on ClinicalTrials.gov

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 16, 2014

Primary Completion Date

June 17, 2015

Study Completion Date

June 17, 2015

Conditions
Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections
Interventions
BIOLOGICAL

Non-adjuvanted low dose of quadrivalent VLP vaccine

A single non-adjuvanted low dose of quadrivalent VLP vaccine

BIOLOGICAL

Non-adjuvanted medium dose of quadrivalent VLP vaccine

A single non-adjuvanted medium dose of quadrivalent VLP vaccine

BIOLOGICAL

Non-adjuvanted high dose of quadrivalent VLP vaccine

A single non-adjuvanted high dose of quadrivalent VLP vaccine

BIOLOGICAL

Adjuvanted low dose of quadrivalent VLP vaccine

A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®

BIOLOGICAL

Adjuvanted high dose of quadrivalent VLP vaccine

A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®

BIOLOGICAL

Placebo

A single dose of placebo

Trial Locations (3)

H9H 4Y6

MUHC-Vaccine Study Centre, Pierrefonds

G1E 7G9

Centre de recherche-CHU de Québec, Québec

G1P 0A2

inVentiv Health Clinique, Québec

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT02236052 - Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population | Biotech Hunter | Biotech Hunter